1114 related articles for article (PubMed ID: 34407851)
1. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Zhao H; Xing C; Zhang J; He B
Reprod Health; 2021 Aug; 18(1):171. PubMed ID: 34407851
[TBL] [Abstract][Full Text] [Related]
2. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Morley LC; Tang T; Yasmin E; Norman RJ; Balen AH
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD003053. PubMed ID: 29183107
[TBL] [Abstract][Full Text] [Related]
3. Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
Xing C; Li C; He B
J Clin Endocrinol Metab; 2020 Sep; 105(9):2950-63. PubMed ID: 32490533
[TBL] [Abstract][Full Text] [Related]
4. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Tang T; Lord JM; Norman RJ; Yasmin E; Balen AH
Cochrane Database Syst Rev; 2012 May; (5):CD003053. PubMed ID: 22592687
[TBL] [Abstract][Full Text] [Related]
5. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Lord JM; Flight IH; Norman RJ
Cochrane Database Syst Rev; 2003; (3):CD003053. PubMed ID: 12917943
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.
Yang S; Zhao L; He W; Mi Y
Drugs; 2022 Sep; 82(14):1469-1480. PubMed ID: 36129662
[TBL] [Abstract][Full Text] [Related]
7. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Tang T; Lord JM; Norman RJ; Yasmin E; Balen AH
Cochrane Database Syst Rev; 2010 Jan; (1):CD003053. PubMed ID: 20091537
[TBL] [Abstract][Full Text] [Related]
8. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Costello M; Shrestha B; Eden J; Sjoblom P; Johnson N
Cochrane Database Syst Rev; 2007 Jan; (1):CD005552. PubMed ID: 17253562
[TBL] [Abstract][Full Text] [Related]
9. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Tang T; Lord JM; Norman RJ; Yasmin E; Balen AH
Cochrane Database Syst Rev; 2009 Oct; (4):CD003053. PubMed ID: 19821299
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial.
Jethaliya H; Gajjar N; Patel V; Deshpande S; Patel R
Reprod Sci; 2022 Aug; 29(8):2282-2298. PubMed ID: 35477841
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Fruzzetti F; Perini D; Russo M; Bucci F; Gadducci A
Gynecol Endocrinol; 2017 Jan; 33(1):39-42. PubMed ID: 27808588
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
Pustotina O; Myers SH; Unfer V; Rasulova I
Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
Nazirudeen R; Sridhar S; Priyanka R; Sumathi B; Natarajan V; Subbiah E; Raghavan KS; Sangumani J
Clin Endocrinol (Oxf); 2023 Aug; 99(2):198-205. PubMed ID: 37265016
[TBL] [Abstract][Full Text] [Related]
14. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials.
Facchinetti F; Orrù B; Grandi G; Unfer V
Gynecol Endocrinol; 2019 Mar; 35(3):198-206. PubMed ID: 30614282
[TBL] [Abstract][Full Text] [Related]
15. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
Minozzi M; Nordio M; Pajalich R
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
[TBL] [Abstract][Full Text] [Related]
16. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial.
Shokrpour M; Foroozanfard F; Afshar Ebrahimi F; Vahedpoor Z; Aghadavod E; Ghaderi A; Asemi Z
Gynecol Endocrinol; 2019 May; 35(5):406-411. PubMed ID: 30608001
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
Zhang J; Xing C; Cheng X; He B
Front Endocrinol (Lausanne); 2022; 13():1003238. PubMed ID: 36147577
[TBL] [Abstract][Full Text] [Related]
18. Insulin sensitizers in adolescents with polycystic ovary syndrome.
LE TN; Wickham EP; Nestler JE
Minerva Pediatr; 2017 Oct; 69(5):434-443. PubMed ID: 28497664
[TBL] [Abstract][Full Text] [Related]
19. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
[TBL] [Abstract][Full Text] [Related]
20. WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome.
Tang T; Lord JM; Norman RJ; Yasmin E; Balen AH
Cochrane Database Syst Rev; 2009 Jul; (3):CD003053. PubMed ID: 19588338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
